7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Inflammation D007249 119 associated lipids
Insulin Resistance D007333 99 associated lipids
Jaw Diseases D007571 4 associated lipids
Jaw, Edentulous D007575 1 associated lipids
Jaw, Edentulous, Partially D007576 1 associated lipids
Kidney Diseases D007674 29 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Labyrinthitis D007762 2 associated lipids
Legg-Calve-Perthes Disease D007873 1 associated lipids
Leukemia D007938 74 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Lung Neoplasms D008175 171 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lymphatic Metastasis D008207 10 associated lipids
Lymphocytosis D008218 2 associated lipids
Macular Degeneration D008268 5 associated lipids
Malocclusion D008310 3 associated lipids
Malocclusion, Angle Class I D008311 1 associated lipids
Mandibular Diseases D008336 5 associated lipids
Mandibular Injuries D008338 1 associated lipids
Measles D008457 3 associated lipids
Mitral Valve Insufficiency D008944 4 associated lipids
Mitral Valve Stenosis D008946 3 associated lipids
Fluorosis, Dental D009050 1 associated lipids
Mucocutaneous Lymph Node Syndrome D009080 9 associated lipids
Multiple Myeloma D009101 13 associated lipids
Musculoskeletal Diseases D009140 2 associated lipids
Cardiomyopathies D009202 10 associated lipids
Myocardial Infarction D009203 21 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Neoplasms, Experimental D009374 10 associated lipids
Neoplastic Syndromes, Hereditary D009386 1 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Nerve Degeneration D009410 53 associated lipids
Neuroblastoma D009447 66 associated lipids
Obesity D009765 29 associated lipids
Obesity, Morbid D009767 8 associated lipids
Ossification, Heterotopic D009999 2 associated lipids
Osteitis D010000 10 associated lipids
Osteitis Deformans D010001 3 associated lipids
Osteoarthritis D010003 4 associated lipids
Osteolysis D010014 8 associated lipids
Osteolysis, Essential D010015 1 associated lipids
Osteonecrosis D010020 5 associated lipids
Osteopetrosis D010022 1 associated lipids
Osteoporosis D010024 12 associated lipids
Osteosclerosis D010026 2 associated lipids
Otosclerosis D010040 2 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Respirovirus Infections D010253 3 associated lipids
Paraneoplastic Syndromes D010257 4 associated lipids
Periapical Diseases D010483 4 associated lipids
Periapical Granuloma D010484 3 associated lipids
Periapical Periodontitis D010485 6 associated lipids
Pericardial Effusion D010490 2 associated lipids
Familial Mediterranean Fever D010505 12 associated lipids
Periodontal Diseases D010510 15 associated lipids
Periodontal Pocket D010514 9 associated lipids
Periodontitis D010518 22 associated lipids
Aggressive Periodontitis D010520 8 associated lipids
Periostitis D010522 1 associated lipids
Polycystic Ovary Syndrome D011085 14 associated lipids
Polycythemia Vera D011087 13 associated lipids
Prediabetic State D011236 1 associated lipids
Pregnancy Complications, Hematologic D011250 11 associated lipids
Prenatal Exposure Delayed Effects D011297 2 associated lipids
Progeria D011371 3 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Prosthesis Failure D011475 1 associated lipids
Radicular Cyst D011842 2 associated lipids
Rheumatic Fever D012213 1 associated lipids
Rheumatic Diseases D012216 7 associated lipids
Root Resorption D012391 2 associated lipids
Rupture, Spontaneous D012422 1 associated lipids
Sarcoma, Ewing D012512 2 associated lipids
Osteosarcoma D012516 50 associated lipids
Scleroderma, Systemic D012595 16 associated lipids
Sclerosis D012598 5 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Stomatitis D013280 14 associated lipids
Synovitis D013585 15 associated lipids
Synovitis, Pigmented Villonodular D013586 1 associated lipids
Takayasu Arteritis D013625 3 associated lipids
Temporomandibular Joint Disorders D013705 4 associated lipids
Thinness D013851 11 associated lipids
Thyroid Diseases D013959 8 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Tinnitus D014012 4 associated lipids
Tooth Migration D014085 2 associated lipids
Tooth Mobility D014086 2 associated lipids
Tooth Resorption D014091 1 associated lipids
Uremia D014511 33 associated lipids
Urologic Neoplasms D014571 2 associated lipids
Vascular Diseases D014652 16 associated lipids
Vision Disorders D014786 10 associated lipids
Vitamin D Deficiency D014808 13 associated lipids
Wounds and Injuries D014947 20 associated lipids
Osteoarthritis, Hip D015207 4 associated lipids
Weight Gain D015430 101 associated lipids
Weight Loss D015431 56 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Gravallese EM et al. The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. 2001 Arthritis Res. pmid:11178122
Takemura M et al. Relationship between osteoprotegerin/osteoclastogenesis inhibitory factor concentration in synovial fluid and disease severity in individuals with osteoarthritis of the knee. 2001 Metab. Clin. Exp. pmid:11172466
Wuyts W et al. Evaluation of the role of RANK and OPG genes in Paget's disease of bone. 2001 Bone pmid:11165949
Brändström H et al. Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. 2001 Biochem. Biophys. Res. Commun. pmid:11162596
Hofbauer LC et al. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. 2001 Biochem. Biophys. Res. Commun. pmid:11162519
Yun TJ et al. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. 2001 J. Immunol. pmid:11160187
Browner WS et al. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. 2001 J. Clin. Endocrinol. Metab. pmid:11158021
Wan M et al. Transcriptional mechanisms of bone morphogenetic protein-induced osteoprotegrin gene expression. 2001 J. Biol. Chem. pmid:11139569
Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. 2000 J. Bone Miner. Res. pmid:11127193
Shalhoub V et al. Characterization of osteoclast precursors in human blood. 2000 Br. J. Haematol. pmid:11122091
Kong YY and Penninger JM Molecular control of bone remodeling and osteoporosis. 2000 Exp. Gerontol. pmid:11121682
Mancini L et al. Modulation of the effects of osteoprotegerin (OPG) ligand in a human leukemic cell line by OPG and calcitonin. 2000 Biochem. Biophys. Res. Commun. pmid:11118297
Takayanagi H et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. 2000 Nature pmid:11117749
Proposed standard nomenclature for new tumor necrosis factor members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. 2000 Bone pmid:11113385
Miyamoto T et al. An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor kappa B ligand. 2000 Blood pmid:11110710
Gori F et al. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. 2000 Endocrinology pmid:11108292
Takami M et al. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts. 2000 Endocrinology pmid:11108286
Lee ZH et al. Activation of c-Jun N-terminal kinase and activator protein 1 by receptor activator of nuclear factor kappaB. 2000 Mol. Pharmacol. pmid:11093794
Riggs BL The mechanisms of estrogen regulation of bone resorption. 2000 J. Clin. Invest. pmid:11086020
Sakuma Y et al. Impaired bone resorption by lipopolysaccharide in vivo in mice deficient in the prostaglandin E receptor EP4 subtype. 2000 Infect. Immun. pmid:11083800
Kong YY et al. Osteoprotegerin ligand: a regulator of immune responses and bone physiology. 2000 Immunol. Today pmid:11071528
Kinpara K et al. Osteoclast differentiation factor in human osteosarcoma cell line. 2000 J Immunoassay pmid:11071251
Miyamoto N et al. Spindle-shaped cells derived from giant-cell tumor of bone support differentiation of blood monocytes to osteoclast-like cells. 2000 J. Orthop. Res. pmid:11052502
Fata JE et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. 2000 Cell pmid:11051546
Kaneda T et al. Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor. 2000 J. Immunol. pmid:11035059
Zhang YH et al. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. 2001 J. Biol. Chem. pmid:11032840
Kobayashi Y et al. Force-induced osteoclast apoptosis in vivo is accompanied by elevation in transforming growth factor beta and osteoprotegerin expression. 2000 J. Bone Miner. Res. pmid:11028444
Børset M et al. Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. 2000 Blood pmid:11001907
Teng YT et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. 2000 J. Clin. Invest. pmid:10995794
Lorenzo J Interactions between immune and bone cells: new insights with many remaining questions. 2000 J. Clin. Invest. pmid:10995785
Schinke T and Karsenty G Vascular calcification--a passive process in need of inhibitors. 2000 Nephrol. Dial. Transplant. pmid:10978374
Itoh K et al. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. 2000 J. Bone Miner. Res. pmid:10976996
Nakashima T et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. 2000 Biochem. Biophys. Res. Commun. pmid:10973797
Teitelbaum SL Bone resorption by osteoclasts. 2000 Science pmid:10968780
Yasuda H [A new paradigm of osteoclast biology: discovery of OCIF and ODF]. 2000 Seikagaku pmid:10967683
Udagawa N et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. 2000 Endocrinology pmid:10965921
López FJ New approaches to the treatment of osteoporosis. 2000 Curr Opin Chem Biol pmid:10959765
Shiba H et al. Effects of ageing on proliferative ability, and the expressions of secreted protein, acidic and rich in cysteine (SPARC) and osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human periodontal ligament cells. 2000 Mech. Ageing Dev. pmid:10958924
Min H et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. 2000 J. Exp. Med. pmid:10952716
Quinn JM et al. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. 2000 J. Bone Miner. Res. pmid:10934644
Lacey DL et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. 2000 Am. J. Pathol. pmid:10934148
Hofbauer LC and Heufelder AE Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. 2000 J. Clin. Endocrinol. Metab. pmid:10902778
Tsurukai T et al. Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis. 2000 J. Bone Miner. Metab. pmid:10874596
Rani CS and MacDougall M Dental cells express factors that regulate bone resorption. 2000 Mol. Cell Biol. Res. Commun. pmid:10860862
Günther T and Schinke T Mouse genetics have uncovered new paradigms in bone biology. 2000 Trends Endocrinol. Metab. pmid:10856921
Thirunavukkarasu K et al. The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function. 2000 J. Biol. Chem. pmid:10833509
Kanzawa M et al. Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells. 2000 Eur. J. Endocrinol. pmid:10822231
Malyankar UM et al. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. 2000 J. Biol. Chem. pmid:10811631
Onyia JE et al. In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. 2000 J. Bone Miner. Res. pmid:10804015
Honore P et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. 2000 Nat. Med. pmid:10802707
Thompson SW and Tonge D Bone cancer gain without the pain. 2000 Nat. Med. pmid:10802700
Aubin JE and Bonnelye E Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. 2000 Medscape Womens Health pmid:10792853
Atkins GJ et al. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. 2000 J. Bone Miner. Res. pmid:10780856
Mukohyama H et al. The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK. 2000 Biochem. Biophys. Res. Commun. pmid:10777696
Bateman TA et al. Osteoprotegerin mitigates tail suspension-induced osteopenia. 2000 Bone pmid:10773583
Ross FP RANKing the importance of measles virus in Paget's disease. 2000 J. Clin. Invest. pmid:10712423
Capparelli C et al. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. 2000 Cancer Res. pmid:10706080
Huang L et al. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. 2000 Am. J. Pathol. pmid:10702390
Takayanagi H et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. 2000 Arthritis Rheum. pmid:10693864
Merewether LA et al. Development of disulfide peptide mapping and determination of disulfide structure of recombinant human osteoprotegerin chimera produced in Escherichia coli. 2000 Arch. Biochem. Biophys. pmid:10683254
Makhluf HA et al. Age-related decline in osteoprotegerin expression by human bone marrow cells cultured in three-dimensional collagen sponges. 2000 Biochem. Biophys. Res. Commun. pmid:10679262
Tricot G New insights into role of microenvironment in multiple myeloma. 2000 Lancet pmid:10675068
Hofbauer LC et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. 2000 J. Bone Miner. Res. pmid:10646108
Chikatsu N et al. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. 2000 Biochem. Biophys. Res. Commun. pmid:10631114
Itonaga I et al. Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages. 2000 Ann. Rheum. Dis. pmid:10627423
Yamashita T et al. Retardation in bone resorption after bone marrow ablation in klotho mutant mice. 2000 Endocrinology pmid:10614667
Kong YY et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. 1999 Nature pmid:10580503
Nakagawa N et al. Basic fibroblast growth factor induces osteoclast formation by reciprocally regulating the production of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in mouse osteoblastic cells. 1999 Biochem. Biophys. Res. Commun. pmid:10548507
Nakagawa N et al. Basic fibroblast growth factor inhibits osteoclast formation induced by 1alpha,25-dihydroxyvitamin D(3) through suppressing the production of osteoclast differentiation factor. 1999 Biochem. Biophys. Res. Commun. pmid:10548488
Itonaga I et al. 1,25-Dihydroxyvitamin D(3) and prostaglandin E(2) act directly on circulating human osteoclast precursors. 1999 Biochem. Biophys. Res. Commun. pmid:10529407
Thomas RJ et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. 1999 Endocrinology pmid:10499498
Hofbauer LC et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. 1999 Endocrinology pmid:10499489
Wickelgren I Mining the genome for drugs. 1999 Science pmid:10475849
Hofbauer LC Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. 1999 Eur. J. Endocrinol. pmid:10474114
Lazner F et al. Osteopetrosis and osteoporosis: two sides of the same coin. 1999 Hum. Mol. Genet. pmid:10469835
Sakata M et al. Expression of osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human dental mesenchymal cells and epithelial cells. 1999 J. Bone Miner. Res. pmid:10469276
Morony S et al. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. 1999 J. Bone Miner. Res. pmid:10469275
Hofbauer LC et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. 1999 Endocrinology pmid:10465311
Ito H et al. Hedgehog signaling molecules in bone marrow cells at the initial stage of fracture repair. 1999 Biochem. Biophys. Res. Commun. pmid:10462495
Lee SK and Lorenzo JA Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. 1999 Endocrinology pmid:10433211
Roodman GD Cell biology of the osteoclast. 1999 Exp. Hematol. pmid:10428500
Yasuda H et al. A novel molecular mechanism modulating osteoclast differentiation and function. 1999 Bone pmid:10423033
Spelsberg TC et al. The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. 1999 Mol. Endocrinol. pmid:10379881
Zhang XD et al. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. 1999 Cancer Res. pmid:10364001
Yano K et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. 1999 J. Bone Miner. Res. pmid:10234572
Kong YY et al. Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development. 1999 Immunol. Cell Biol. pmid:10234557
Burgess TL et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. 1999 J. Cell Biol. pmid:10225954
Nagai M and Sato N Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation. 1999 Biochem. Biophys. Res. Commun. pmid:10208850
Hsu H et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. 1999 Proc. Natl. Acad. Sci. U.S.A. pmid:10097072
Shalhoub V et al. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors. 1999 J. Cell. Biochem. pmid:10022507
pmid:

Table of Content